BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1909978)

  • 1. A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients.
    Polson DW; MacLachlan V; Krapez JA; Wood C; Healy DL
    Fertil Steril; 1991 Sep; 56(3):509-14. PubMed ID: 1909978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization.
    MacLachlan V; Besanko M; O'Shea F; Wade H; Wood C; Trounson A; Healy DL
    N Engl J Med; 1989 May; 320(19):1233-7. PubMed ID: 2496310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian response and pregnancy rates in in vitro fertilization, gamete intrafallopian transfer, and in vivo fertilization therapies after combined gonadotropin-releasing hormone agonist/human menopausal gonadotropin stimulation.
    Lindner C; Braendle W; Lichtenberg V; Köhler S; Bettendorf G
    Gynecol Obstet Invest; 1990; 29(2):140-4. PubMed ID: 2139861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term utilization of a gonadotropin-releasing hormone agonist (buserelin) for induction of ovulation in an in vitro fertilization program.
    Loumaye E; de Cooman S; Anoma M; Psalti I; Depreester S; Schmit M; Thomas K
    Ann N Y Acad Sci; 1988; 541():96-102. PubMed ID: 3143299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ovarian stimulation regimens for in vitro fertilization (IVE) with and without a gonadotropin-releasing hormone (GnRH) agonist: results of a randomized study.
    van de-Helder AB; Helmerhorst FM; Blankhart A; Brand R; Waegemaekers C; Naaktgeboren N
    J In Vitro Fert Embryo Transf; 1990 Dec; 7(6):358-62; discussion 363-4. PubMed ID: 2127604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a gonadotropin-releasing hormone agonist and gonadotropins on ovarian follicles in cynomolgus monkey: a model for human ovarian hyperstimulation.
    Lefèvre B; Gougeon A; Nomé F; Testart J
    Fertil Steril; 1991 Jul; 56(1):119-25. PubMed ID: 1906016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of different ovarian stimulation protocols for in vitro fertilization.
    Pados G; Tarlatzis BC; Bontis J; Lagos S; Papadimas J; Spanos E; Mantalenakis S
    Gynecol Endocrinol; 1995 Jun; 9(2):103-12. PubMed ID: 7502685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The results of an in vitro fertilization program: two regimens of superovulation.
    Grochowski D; Wołczyński S; Kuczyński W; Kulikowski M; Szamatowicz M
    Gynecol Endocrinol; 1995 Mar; 9(1):59-62. PubMed ID: 7793301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins for in vitro fertilization or gamete intrafallopian transfer.
    Ferrier A; Rasweiler JJ; Bedford JM; Prey K; Berkeley AS
    Fertil Steril; 1990 Jul; 54(1):90-5. PubMed ID: 2113492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular monitoring and outcome of in vitro fertilization in gonadotropin-releasing hormone-agonist-treated cycles.
    Forman RG; Robinson J; Egan D; Ross C; Gosden B; Barlow DH
    Fertil Steril; 1991 Mar; 55(3):567-73. PubMed ID: 1900482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined treatment with a GnRH-analog and gonadotropins in IVF-ET/GIFT patients after previously unsuccessful pure HMG stimulation].
    Urbancsek J; Rabe T; Grunwald K; Thuro H; Runnebaum B
    Zentralbl Gynakol; 1991; 113(10):563-74. PubMed ID: 1927104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro fertilization with low-dose clomiphene citrate stimulation in women who respond poorly to superovulation.
    Awonuga AO; Nabi A
    J Assist Reprod Genet; 1997 Oct; 14(9):503-7. PubMed ID: 9401867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct effect of gonadotropin-releasing hormone agonists on the rabbit ovarian follicle.
    Yoshimura Y; Nakamura Y; Ando M; Shiokawa S; Koyama N; Nanno T
    Fertil Steril; 1992 May; 57(5):1091-7. PubMed ID: 1572478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program.
    Abdalla HI; Ahuja KK; Leonard T; Morris NN; Honour JW; Jacobs HS
    Fertil Steril; 1990 Mar; 53(3):473-8. PubMed ID: 2106453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
    Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
    Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin.
    Tan SL; Maconochie N; Doyle P; Campbell S; Balen A; Bekir J; Brinsden P; Edwards RG; Jacobs HS
    Am J Obstet Gynecol; 1994 Aug; 171(2):513-20. PubMed ID: 8059833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of the GnRH analogue buserelin for IVF--does it improve fertility?
    Shelton K; Fishel S; Jackson P; Webster J; Faratian B; Johnson J
    Br J Obstet Gynaecol; 1991 Jun; 98(6):544-9. PubMed ID: 1908314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.